# Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)

> **NCT04597671** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Association NVALT Studies** · enrollment: 170 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Durvalumab
- **RADIATION:** low-dose PCI

## Key facts

- **NCT ID:** NCT04597671
- **Lead sponsor:** Association NVALT Studies
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-06
- **Primary completion:** 2028-12
- **Final completion:** 2032-12
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04597671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04597671, "Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04597671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*